Doma and its affiliate, Xadcera, officially received IND clearance from U.S. FDA for their first bispecific ADC asset, DM001.

On June 1, 2022, Doma Biopharmaceutical (Suzhou) Co., Ltd. announced the completion of a round A financing of 950 million rmb.

Establishment of Doma's incubation company

Establishment of Doma's first incubation company

Signing ceremony held in Suzhou on October 20, 2021

Established in Suzhou Industrial Park on September 16, 2021